Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
31.5M
-
Shares change
-
+101K
-
Total reported value, excl. options
-
$1.44B
-
Value change
-
-$1.91M
-
Put/Call ratio
-
0.06
-
Number of buys
-
83
-
Number of sells
-
-56
-
Price
-
$45.70
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q2 2024
174 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2024.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.5M shares
of 40.6M outstanding shares and own 77.47% of the company stock.
Largest 10 shareholders include FMR LLC (4.72M shares), BlackRock Inc. (2.51M shares), VANGUARD GROUP INC (1.76M shares), ALKEON CAPITAL MANAGEMENT LLC (1.6M shares), Darwin Global Management, Ltd. (1.53M shares), ORBIMED ADVISORS LLC (1.27M shares), STATE STREET CORP (1.22M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.19M shares), BRAIDWELL LP (982K shares), and Jefferies Financial Group Inc. (899K shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.